Medical expenditure for lung cancer in China: a multicenter, hospital-based retrospective survey.
Cost Eff Resour Alloc
; 19(1): 53, 2021 Aug 17.
Article
en En
| MEDLINE
| ID: mdl-34404418
ABSTRACT
BACKGROUND:
Lung cancer is the most prevalent cancer, and the leading cause of cancer-related deaths in China. The aim of this study was to estimate the direct medical expenditure incurred for lung cancer care and analyze the trend therein for the period 2002-2011 using nationally representative data in ChinaMETHODS:
This study was based on 10-year, multicenter retrospective expenditure data collected from hospital records, covering 15,437 lung cancer patients from 13 provinces diagnosed during the period 2002-2011. All expenditure data were adjusted to 2011 to eliminate the effects of inflation using China's annual consumer price index.RESULTS:
The direct medical expenditure for lung cancer care (in 2011) was 39,015 CNY (US$6,041) per case, with an annual growth rate of 7.55% from 2002 to 2011. Drug costs were the highest proportionally in the total medical expenditure (54.27%), followed by treatment expenditure (14.32%) and surgical expenditure (8.10%). Medical expenditures for the disease varied based on region, hospital level, type, and stage.CONCLUSION:
The medical expenditure for lung cancer care is substantial in China. Drug costs and laboratory test are the main factors increasing medical costs.
Texto completo:
1
Colección:
01-internacional
Banco de datos:
MEDLINE
Tipo de estudio:
Clinical_trials
/
Health_economic_evaluation
Idioma:
En
Revista:
Cost Eff Resour Alloc
Año:
2021
Tipo del documento:
Article
País de afiliación:
China